Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Fineline Cube Mar 27, 2026
Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Fineline Cube Mar 27, 2026
Company Deals

NeuShen Therapeutics Closes $20M Series Pre-A Financing for CNS Drug Development

Fineline Cube Sep 30, 2022

NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round...

Company Drug

Zelgen Files NDA for Jacktinib to Treat Myelofibrosis in China

Fineline Cube Sep 29, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has filed a New...

Company

Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 29, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24...

Company Drug

Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Sep 29, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy...

Company Drug

Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval

Fineline Cube Sep 29, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication...

Company Drug

Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082

Fineline Cube Sep 29, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been...

Company Drug

Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022

Fineline Cube Sep 29, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100...

Company

Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics

Fineline Cube Sep 29, 2022

Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a...

Company

Biosyngen to Establish Cell Therapy GMP Facility in Singapore

Fineline Cube Sep 29, 2022

Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...

Company

Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges

Fineline Cube Sep 29, 2022

China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85...

Company Medical Device

Parexel Opens Clinical Study Supply Chain Center in Suzhou

Fineline Cube Sep 29, 2022

US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply...

Company Drug

Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043

Fineline Cube Sep 29, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...

Company Drug

Arctic Vision Enrolls First Patient in Phase III Study for ARVN002

Fineline Cube Sep 29, 2022

China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a...

Company Deals

3D Medicines Partners with Denfo Medical for Cancer Therapy Development

Fineline Cube Sep 29, 2022

China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group,...

Company Deals

Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278

Fineline Cube Sep 29, 2022

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...

Company Deals

Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion

Fineline Cube Sep 29, 2022

Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured...

Company

Santen Pharmaceutical Launches New Plant Construction in Suzhou

Fineline Cube Sep 28, 2022

Japan-based Santen Pharmaceutical Co. has launched the construction of a new plant in Suzhou, Jiangsu...

Company Drug

Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma

Fineline Cube Sep 28, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and...

Company Deals

Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development

Fineline Cube Sep 28, 2022

Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with...

Company Deals

Merck Sharp & Dohme Partners with Sinopharm for Molnupiravir in China

Fineline Cube Sep 28, 2022

US-based Merck Sharp & Dohme (MSD, NYSE: MRK) has entered into a cooperation framework agreement...

Posts pagination

1 … 595 596 597 … 642

Recent updates

  • C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market
  • Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction
  • CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
  • Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Company

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.